NewLink Genetics Stock Price, News & Analysis (NASDAQ:NLNK)

$1.82
-0.08 (-4.21 %)
(As of 09/23/2019 01:35 AM ET)
Today's Range
$1.77
Now: $1.82
$1.89
50-Day Range
$1.46
MA: $1.67
$2.04
52-Week Range
$1.28
Now: $1.82
$2.60
Volume154,341 shs
Average Volume290,792 shs
Market Capitalization$67.90 million
P/E RatioN/A
Dividend YieldN/A
Beta1.21
NewLink Genetics Corporation, a late clinical-stage immuno-oncology company, focuses on discovering and developing novel immunotherapeutic products for the treatment of patients with cancer. It is developing Indoximod, an indoleamine-2, 3-dioxygenase (IDO) pathway inhibitor that is in clinical development in combination with other cancer therapeutics for patients with diffuse intrinsic pontine glioma, pediatric brain tumors, acute myeloid leukemia, and melanoma. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:NLNK
CUSIP65151110
Phone515-296-5555

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$12.47 million
Book Value$3.09 per share

Profitability

Net Income$-53,600,000.00
Net Margins-6,587.56%

Miscellaneous

Employees55
Market Cap$67.90 million
Next Earnings Date11/7/2019 (Estimated)
OptionableOptionable

Receive NLNK News and Ratings via Email

Sign-up to receive the latest news and ratings for NLNK and its competitors with MarketBeat's FREE daily newsletter.


NewLink Genetics (NASDAQ:NLNK) Frequently Asked Questions

What is NewLink Genetics' stock symbol?

NewLink Genetics trades on the NASDAQ under the ticker symbol "NLNK."

How were NewLink Genetics' earnings last quarter?

NewLink Genetics Corp (NASDAQ:NLNK) announced its quarterly earnings data on Tuesday, July, 30th. The biotechnology company reported ($0.27) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.02. The biotechnology company earned $0.15 million during the quarter. NewLink Genetics had a negative return on equity of 34.44% and a negative net margin of 6,587.56%. View NewLink Genetics' Earnings History.

When is NewLink Genetics' next earnings date?

NewLink Genetics is scheduled to release their next quarterly earnings announcement on Thursday, November 7th 2019. View Earnings Estimates for NewLink Genetics.

What price target have analysts set for NLNK?

2 equities research analysts have issued 1-year price objectives for NewLink Genetics' stock. Their predictions range from $4.00 to $5.00. On average, they anticipate NewLink Genetics' stock price to reach $4.50 in the next twelve months. This suggests a possible upside of 147.3% from the stock's current price. View Analyst Price Targets for NewLink Genetics.

What is the consensus analysts' recommendation for NewLink Genetics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NewLink Genetics in the last year. There are currently 1 sell rating and 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for NewLink Genetics.

Has NewLink Genetics been receiving favorable news coverage?

Media coverage about NLNK stock has trended somewhat negative recently, InfoTrie reports. The research firm ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. NewLink Genetics earned a news sentiment score of -1.3 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for NewLink Genetics.

Are investors shorting NewLink Genetics?

NewLink Genetics saw a drop in short interest during the month of August. As of August 31st, there was short interest totalling 1,216,100 shares, a drop of 18.6% from the July 31st total of 1,493,800 shares. Based on an average daily volume of 358,700 shares, the short-interest ratio is currently 3.4 days. Currently, 4.2% of the company's shares are short sold. View NewLink Genetics' Current Options Chain.

Who are some of NewLink Genetics' key competitors?

What other stocks do shareholders of NewLink Genetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NewLink Genetics investors own include Synergy Pharmaceuticals (SGYP), Arbutus Biopharma (ABUS), Inovio Pharmaceuticals (INO), Celldex Therapeutics (CLDX), Sarepta Therapeutics (SRPT), SunPower (SPWR), Alibaba Group (BABA), Novavax (NVAX), Opko Health (OPK) and FireEye (FEYE).

Who are NewLink Genetics' key executives?

NewLink Genetics' management team includes the folowing people:
  • Dr. Charles J. Link Jr., Co-Founder, Chairman, CEO & Chief Scientific Officer (Age 60)
  • Mr. Nicholas N. Vahanian, Co-Founder, Pres, Chief Medical Officer & Director (Age 52)
  • Dr. Eugene P. Kennedy M.D., FACS, Chief Medical Officer (Age 50)
  • Mr. Brian Wiley, Chief Commercial Officer (Age 51)
  • Mr. Carl W. Langren, CFO & Principal Accounting Officer (Age 64)

Who are NewLink Genetics' major shareholders?

NewLink Genetics' stock is owned by a number of of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (7.85%), Vanguard Group Inc. (3.79%), Connor Clark & Lunn Investment Management Ltd. (1.56%), Acadian Asset Management LLC (1.47%), BlackRock Inc. (1.44%) and Northern Trust Corp (0.89%). Company insiders that own NewLink Genetics stock include Carl W Langren, Ernest Talarico III and Stine Seed Farm, Inc. View Institutional Ownership Trends for NewLink Genetics.

Which institutional investors are selling NewLink Genetics stock?

NLNK stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Panagora Asset Management Inc., Wells Fargo & Company MN, Bank of New York Mellon Corp, Connor Clark & Lunn Investment Management Ltd., Parametric Portfolio Associates LLC and Northern Trust Corp. View Insider Buying and Selling for NewLink Genetics.

Which institutional investors are buying NewLink Genetics stock?

NLNK stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Renaissance Technologies LLC, Acadian Asset Management LLC, Paloma Partners Management Co, Requisite Capital Management LLC, Jane Street Group LLC, Worth Venture Partners LLC and Tower Research Capital LLC TRC . View Insider Buying and Selling for NewLink Genetics.

How do I buy shares of NewLink Genetics?

Shares of NLNK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is NewLink Genetics' stock price today?

One share of NLNK stock can currently be purchased for approximately $1.82.

How big of a company is NewLink Genetics?

NewLink Genetics has a market capitalization of $67.90 million and generates $12.47 million in revenue each year. The biotechnology company earns $-53,600,000.00 in net income (profit) each year or ($1.44) on an earnings per share basis. NewLink Genetics employs 55 workers across the globe.View Additional Information About NewLink Genetics.

What is NewLink Genetics' official website?

The official website for NewLink Genetics is http://www.newlinkgenetics.com/.

How can I contact NewLink Genetics?

NewLink Genetics' mailing address is 2503 SOUTH LOOP DRIVE, AMES IA, 50010. The biotechnology company can be reached via phone at 515-296-5555 or via email at [email protected]


MarketBeat Community Rating for NewLink Genetics (NASDAQ NLNK)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  350 (Vote Outperform)
Underperform Votes:  278 (Vote Underperform)
Total Votes:  628
MarketBeat's community ratings are surveys of what our community members think about NewLink Genetics and other stocks. Vote "Outperform" if you believe NLNK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NLNK will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/23/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel